Serono Onercept Psoriasis Studies Discontinued Due To Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Serono is discontinuing development of its anti-tumor necrosis factor agent onercept for moderate-to-severe psoriasis based on cases of sepsis reported during Phase III trials, the company said April 6
You may also be interested in...
Canvaxin Melanoma Vaccine BLA Delayed Until 2007 After Trial Fails
Serono/CancerVax data safety monitoring board recommends halting Phase III development of Canvaxin for Stage IV melanoma due to lack of efficacy. Pivotal program for Stage III disease continues; no safety issues were identified with either study.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.